ATAI Life Sciences (ATAI) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on ATAI Life Sciences (ATAIResearch Report) today and set a price target of $50.00. The company’s shares opened today at $1.50.

According to TipRanks, Trucchio is an analyst with an average return of -15.9% and a 32.14% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as uniQure, Alnylam Pharma, and Sangamo Biosciences.

Currently, the analyst consensus on ATAI Life Sciences is a Strong Buy with an average price target of $22.71, which is a 1,414.00% upside from current levels. In a report released today, EF Hutton also maintained a Buy rating on the stock with a $15.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $7.02 and a one-year low of $2.34. Currently, ATAI Life Sciences has an average volume of 1.04M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.

Read More on ATAI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed